Abstract
The analysis of antigenic and immunogenic properties of tumor cells and of mechanisms of antitumor response should furnish the basis for the investigation of methods aimed at immunotherapy of malignant diseases. One may expect that such methods will be especially effective in the prevention of metastatic progression following surgical removal of the primary tumor mass. Immunotherapeutic approaches are based either on nonspecific stimulation of the host’s immune system or on the specific immunization of the organism against tumor cells originating in the surgically removed tumor. These immunization procedures are expected to stimulate the development of cytotoxic lymphocytes or antibodies which are capable of inhibiting tumor growth and destroying metastatic tumor cells. Another experimental approach to immunotherapy is based on the adoptive transfer to the diseased host of lymphocytes sensitized in vitro against tumor cells [1].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Rosenberg S, Terry W: Passive immunotherapy of cancer in animals and man. Adv Cancer Res 25:323–388, 1977.
Fidler I, Gersten D, Hart I: The biology of cancer invasion and metastasis. Adv Cancer Res 28:149–250, 1978.
Fidler I, Nicolson G: Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J Natl Cancer Inst 57:1199–1202, 1976.
Liotta L, Tryggvason K, Garbisa S, Gehron Robey P, Murray J: Interaction of metastatic tumor cells with basement membrane collagen. In: Cancer campaign, Vol. 4, Metastatic tumor growth. Grundmann, E (ed). New York: Gustav Fisher Verlag, 1980, pp 21–30.
Gorelik E, Fogel M, Segal S, Feldman M: Tumor-associated antigenic differences between the primary and the descendant metastatic tumor cell populations. J Supramol Struct 12:385–402, 1979.
Trope C: Different sensitivity to cytostatic drugs of primary tumor and metastasis of the Lewis carcinoma. Neoplasma 22:171–180, 1975.
Nicolson G: Cell surfaces and blood-borne tumor metastasis. In: Cancer invasion and metastasis: biological mechanisms and therapy. Day SB et al. (eds). New York: Raven Press, 1977, pp 168–174.
Hart L, Talmage J, Fidler I: Metastatic behavior of a murine reticulum cell sarcoma exhibiting organ-specific growth. Cancer Res 41:1281–1287, 1981.
Rabotti G: Ploidy of primary and metastatic human tumors. Nature 183:1276–1277, 1959.
Chu E, Malmgren R: Microspectrophotometric determination of deoxyribonucleic acid in primary and metastatic mouse mammary tumors. J Natl Cancer Inst 27:217–220, 1961.
Chatterjee S, Kim U: Fucosyl-transferase activity in metastasizing and nonmetastasizing rat mammary carcinomas. J Natl Cancer Inst 61:151–162, 1978.
Gershon R, Carter R: Facilitation of metastatic growth by antilymphocyte serum. Nature 226:368–370, 1970.
Jones P, Castro J: Immunological mechanisms in metastatic spread and the antimetastatic effects of C. parvum. Br J Cancer 35:519–527, 1977
Alexander P, Eccles S: The contribution of immunological factors to the control of metastatic spread of sarcomata in rats. In: Critical factors in cancer immunology, Vol. 10, Shultz J, Leif E (eds). New York: Academic Press 1975, pp 159–171.
Fogel M, Gorelik E, Segal S, Feldman M: Differences in cell surface antigens of tumor metastases and those of the local tumor. J Natl Cancer Inst 62:585–588, 1979.
Gorelik E, Fogel M, Feldman M, Segal S: Differences in resistance of metastatic tumor cells and cells from local tumor growth to cytotoxicity of natural killer cells. J Natl Cancer Inst 63:1397–1404, 1979.
Gorelik E, Feldman M, Segal S: Selection of 3LL tumor subline resistant to natural effector cells concomitantly selected for increased metastatic potency. Immunol Immunother Cancer (in press).
Baetselier P, Katzav S, Gorelik E, Feldman H, Segal S: Differential expression of the H-2 gene products in tumour cells is associated with their metastatogenic properties. Nature 288:179–181, 1980.
Fogel M, Segal S, Gorelik E, Feldman M: Specific cytotoxic lymphocytes against syngeneic, but not xenogeneic, serum. Int J Cancer 22:329–334, 1978
Sugarbaker E, Cohen A: Altered antigenicity in spontaneous pulmonary metastases from an antigenic murine sarcoma. Surgery 72:155–161, 1972.
Schirrmacher V, Bosslet K, Shantz G, Clauer K, Hubsch D: Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. IV. Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes. Int J Cancer 23:245–252, 1979.
Herberman R, Holden H: Natural cell-mediated immunity. Adv Cancer Res 7:305–377, 1978.
Kiessling R, Wigzell H: An analysis of the murine NK cell as to structure, function and biological relevance. Immunol Rev 44:166–208, 1979.
Liotta L, Vembu D, Saini R, Boone C: In vivo monitoring of the death rate of artificial murine pulmonary micrometastases. Cancer Res 38:1231–1236, 1978.
Riccardi C, Puccetti P, Santoni A, Herberman R: Rapid In vivo assay of mouse natural killer (NK) cell activity. J Natl Cancer Inst 63:1041–1045, 1979.
Hanna N, Fidler I: The role of natural killer cells in the destruction of circulating tumor emboli. J Natl Cancer Inst 65:801–809, 1980.
Hanna N, Fidler I, Relationship between metastatic potential and resistance to NK cell mediated cytotoxicity in three murine tumor systems. J Natl Cancer Inst 66:1183–1190, 1981.
Gorelik E, Fogel M, Segal S, Feldman M: Antigenic differences between local 3LL tumor and its metastases. III. Difference in growth rate in syngeneic, semiallogeneic and allogeneic hosts. Ninth Annual Meeting of the Israel Immunological Society 35: 1978.
Isakow N, Feldman M, Segal S: Genetic regulation of metastatic progression: the development of pulmonary metastases of the 3LL lung carcinoma is controlled by both non H-2 gene(s) and gene(s) linked to the H-2D region of the mouse MHC. Transp Proc 13:778–782, 1981.
Brodt P, Gordon J: Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor. J Immunol 121:359–365, 1978.
Zinkernagel R, Doherty P: H-2 compatibility requirement for T cell mediated lysis of target cells infected with lymphocytic choriomeningitis virus. Different cytotoxic T cell specificities are associated with structures coded for in H-2K or H-2D. J Exp Med 141:1427–1436, 1975.
Meruelo D, Nimelstein S, Jones P, Lieberman M, McDevit H: Increased synthesis and expression of H-2 antigens on thymocytes as a result of radiation leukemia virus infection: a possible mechanism for H-2 linked control of virus-induced neoplasia. J Exp Med 147:470–487, 1978.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Martinus Nijhoff Publishers, The Hague/Boston/London
About this chapter
Cite this chapter
Gorelik, E., Fogel, M., De Baetselier, P., Katzav, S., Feldman, M., Segal, S. (1982). Immunobiological diversity of metastatic cells. In: Liotta, L.A., Hart, I.R. (eds) Tumor Invasion and Metastasis. Developments in Oncology, vol 7. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-7511-8_9
Download citation
DOI: https://doi.org/10.1007/978-94-009-7511-8_9
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-009-7513-2
Online ISBN: 978-94-009-7511-8
eBook Packages: Springer Book Archive